SGLT2 inhibiting compounds are provided having the formula ##STR1## wherein n is 0, 1 or 2; A is ##STR2## or heteroaryl which may contain 1 to 4 heteroatoms in the ring which may be selected from N, O, S, SO, and/or SO.sub.2, bearing substituents R.sup.3 and R.sup.4 ; and R.sup.1 to R.sup.4 are as defined herein. A method is also provided for treating diabetes and related diseases employing an SGLT2 inhibiting amount of the above compound alone or in combination with one, two or more other antidiabetic agents and/or one, two or more hypolipidemic agents.